Novel drug targets tumor growth in advanced kidney cancer

Harvard researchers at Dana-Farber Cancer Institute have developed a novel targeted drug that shows promise in advanced kidney cancer by interfering with the abnormal blood vessel formation that fuels tumor growth.

Richard Saltus | Feb. 12, 2020 | harvard
~4 mins   

Tags: health-medicine basic-research clear-cell-renal-cell-carcinoma dana-farber-cancer-institute hypoxia-inducible-factor kidney-cancer metastatic-disease mk-6482 nobel-prize phase-iii toni-choueiri tumors william-g-kaelin-jr

Study finds racial disparities in culturally competent cancer care

A new study from Harvard-affiliated Dana-Farber Cancer Institute finds that non-white minority survivors are less likely than non-Hispanic whites to be seen by cancer specialists who share or understand their culture.

Richard Saltus | Nov. 1, 2019 | harvard
~5 mins   

Tags: health-medicine brandon-a-mahal cancer-specialists dana-farber-cancer-institute hispanic minorities non-white santino-s-butler

High-dose vitamin D shows benefit in patients with advanced colorectal cancer

The first randomized clinical trial of vitamin D in patients with metastatic colorectal cancer found that high doses of supplements combined with chemotherapy delayed disease progression.

Richard Saltus | April 9, 2019 | harvard
~6 mins   

Tags: health-medicine cancer dana-farber-cancer-institute delayed-disease-progression metastatic-colorectal-cancer phase-3-trial sunshine-clinical-trial vitamin-d

Harvard study finds cells recall their early development

Study in mice reveals that adult tissues retain a memory of which genes are activated during very early development, and that that memory can be recovered. Under certain conditions, adult cells play their developmental “movie” in a slow rewind, reactivating fetal genes. These findings have important implications for regenerative medicine and cancer research.

Jessica Lau | March 21, 2019 | harvard
~5 mins   

Tags: health-medicine brigham-and-womens-hospital cell-memory dana-farber-cancer-institute dfci harvard-medical-school harvard-stem-cell-institute ramesh-shivdasani unmesh-jadhav

Three years after undergoing gene therapy, his ‘last shot’ hit the target

Three years after undergoing gene therapy at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to treat a life-threatening immune disorder, an Ohio college student is no longer thinking about his own “last shot” for health, but rather about medical school and “giving back.”

Alvin Powell | Feb. 21, 2019 | harvard
~17 mins   

Tags: health-medicine alvin-powell becky-whittaker boston-childrens-hospital brenden-whittaker cgd chronic-granulomatous-disease clinical-trial dana-farber-cancer-institute dana-farberboston-childrens-cancer-and-blood-disorders-center david-a-williams gene-therapy

Exercise-related hormone irisin found to target key bone cells

Scientists have discovered that irisin, a hormone released by muscles during exercise, directly acts on key regulatory cells that control the breakdown and formation of bone.

Richard Saltus | Dec. 14, 2018 | harvard
~5 mins   

Tags: health-medicine bone-thinning bruce-spiegelman dana-farber-cancer-institute exercise irisin osteocytes osteoporosis

Researchers identify pathway that drives sustained pain following injury

Harvard researchers have identified in mice a set of neurons responsible for sustained pain and pain-coping behaviors. The new study is the first one to map out how these responses arise outside the brain.

Ekaterina Pesheva | Dec. 13, 2018 | harvard
~8 mins   

Tags: health-medicine blavatnik-institute-at-harvard-medical-school brain dana-farber-cancer-institute ekaterina-pesheva harvard-medical-school neurons pain qiufu-ma signaling-pathways

Page 1 of 1